Phospho-c-Kit (Tyr719) Antibody #3391
- WB
Product Specifications
| REACTIVITY | H M |
| SENSITIVITY | Endogenous |
| MW (kDa) | 120, 145 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
A number of RTK inhibitors have been evaluated in the clinical space in patients with c-Kit driven tumors, beginning with imatinib in 2002 (8). More recently, improved outcomes have been observed with repretinib in patients with advanced, imatinib-resistant GIST (9,10).
- Martin, F.H. et al. (1990) Cell 63, 203-11.
- Yarden, Y. et al. (1987) EMBO J 6, 3341-51.
- Gommerman, J.L. et al. (1997) J Biol Chem 272, 30519-25.
- Sattler, M. et al. (1997) J Biol Chem 272, 10248-53.
- Nocka, K. et al. (1990) EMBO J 9, 1805-13.
- Hirota, S. et al. (1998) Science 279, 577-80.
- Blume-Jensen, P. et al. (2000) Nat Genet 24, 157-62.
- Klug LR et al. (2021) J Clin Oncol 39, 1674-1686.
- Lim SY et al. (2024) Cancers (Basel) 16, 985. doi: 10.3390/cancers16050985.
- Liu WZ et al. (2024) J Dig Dis 25, 559-563.
Alternate Names
C-Kit; c-Kit protooncogene; CD117; ckit; KIT; KIT proto-oncogene, receptor tyrosine kinase; Mast/stem cell growth factor receptor; Mast/stem cell growth factor receptor Kit; MASTC; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; proto-oncogene tyrosine-protein kinase Kit; SCFR; soluble KIT variant 1; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.